Combined Chemotherapy

Goldin, Abraham

doi:10.1159/000225489

Cited by 9 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding that ZBP-89 abolishes HCC cells in the G2-M phase and arrests them in S phase provides a piece of novel information as to how it suppresses the growth of tumor cells. The anti-tumor effectiveness often benefits from the combination of agents that function with complementary inhibition and act at different phases of the cell cycle [27,34]. The anti-tumor mechanism of ZBP-89 may not follow the pathways of 5-FU or STS.…”

Section: Discussionmentioning

confidence: 99%

ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest

et al. 2009

View full text Add to dashboard Cite

ZBP-89 inhibits the some tumor cells but its role in HCC is unknown. We investigated effect of ZBP-89 on cell death of 5 HCC cell lines with different status of p53. We found that ZBP-89 significantly induced cell death of all HCC cells particularly those with wild-type p53. The inhibition was well correlated with the induction of caspase-6 activity. The inhibition of caspase-6 abolished the effect of ZBP-89. ZBP-89 reduced the cells in G2-M but increased them in S phase. With the changes in caspase-6 and cell cycle, ZBP-89 greatly enhanced the killing effectiveness of 5-fluorouracil or staurosporine in HCC cells.

show abstract

Section: Discussionmentioning

confidence: 99%

ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Furthermore, chemotherapeutic combination therapies can reduce drug dosage to patients, lightening side effects while enhancing efficacy (Yu et al, 2018 ; Shrestha et al, 2019 ; Zhang et al, 2019 ). Combination chemotherapy possesses great potential for cancer treatment (Goldin, 1980 ).…”

Section: Introductionmentioning

confidence: 99%

A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies

Gao

Shen

et al. 2020

Front. Chem.

View full text Add to dashboard Cite

Chemotherapy is an important anti-tumor treatment in clinic to date, however, the effectiveness of traditional chemotherapy is limited by its poor selectivity, high systemic toxicity, and multidrug resistance. In recent years, mesoporous silica nanoparticles (MSNs) have become exciting drug delivery systems (DDS) due to their unique advantages, such as easy large-scale production, adjustable uniform pore size, large surface area and pore volumes. While mesoporous silica-based DDS can improve chemotherapy to a certain extent, when used in combination with other cancer therapies MSN based chemotherapy exhibits a synergistic effect, greatly improving therapeutic outcomes. In this review, we discuss the applications of MSN DDS for a diverse range of chemotherapeutic combination anti-tumor therapies, including phototherapy, gene therapy, immunotherapy and other less common modalities. Furthermore, we focus on the characteristics of each nanomaterial and the synergistic advantages of the combination therapies. Lastly, we examine the challenges and future prospects of MSN based chemotherapeutic combination therapies.

show abstract

“…The advantages of combination chemotherapy have been proven numerous times both in vitro and in vivo [21,23,26]. They include the ability to maximize cell death while minimizing toxicity through the use of drugs with nonoverlapping mechanisms of action and toxicities [8,12,26].…”

Section: Introductionmentioning

confidence: 99%

Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines

Scott

Dorr

Samulitis

et al. 2007

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

The consistent synergy seen for imexon and alkylating agents may relate to the sulfhydryl-lowering effect of imexon, which would render cells more sensitive to electrophilic species from the alkylators. The marked synergy noted with pyrimidine-based antimetabolites was unexpected and may relate to the induction of cell cycle arrest in S-phase. The strong antagonism noted for imexon with topoisomerase I and II inhibitors may be due to the effect of imexon at increasing oxidant levels which are known to antagonize the cytotoxic effects of topoisomerase poisons. In contrast, the synergy seen with bortezomib in myeloma cells may be related to an increase in reactive oxygen species (ROS) from both drugs. These results suggest that combinations of imexon with alkylating agents and pyrimidine-based antimetabolites are rational to pursue in therapeutic studies in vivo.

show abstract

Combined Chemotherapy

Cited by 9 publications

References 11 publications

ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest

ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest

A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies

Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines

Contact Info

Product

Resources

About